Advancing quality through innovation

Article

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year's meeting

The CancerNetwork brings you internationally regarded oncologists giving exclusive interviews and expert perspective reports of the highlights of this year's meeting. At the links below you'll find updates from GI specialists Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute

Recent Videos
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
3 experts in this video
3 experts in this video
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Related Content
Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies

Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies

Jordyn Sava
December 12th 2024
Article

Data shown at ASH 2024 demonstrated higher OS rates with anti-CD20 antibodies in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

Kristi Rosa
December 12th 2024
Article

For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Active Monitoring Noninferior to Standard Surgery, RT in Low-risk DCIS

Active Monitoring Noninferior to Standard Surgery, RT in Low-risk DCIS

Gina Mauro
December 12th 2024
Article

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Real-World Data Show No OS Difference Among CDK4/6 Inhibitor Combos in HR+/HER2– MBC

Real-World Data Show No OS Difference Among CDK4/6 Inhibitor Combos in HR+/HER2– MBC

Morgan Bayer
December 12th 2024
Article

Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.